Kuros Biosciences Ltd. (CH:KURN)
:KURN
KURN Stock Chart & Stats
CHF28.16
-CHF0.35(-1.68%)
At close: 4:00 PM EST
CHF28.16
-CHF0.35(-1.68%)
Day’s Range― - ―
52-Week RangeCHF14.00 - CHF34.20
Previous CloseN/A
Volume98.33K
Average Volume (3M)128.87K
Market Cap
CHF910.53M
Enterprise ValueCHF898.80M
Total Cash (Recent Filing)CHF15.66M
Total Debt (Recent Filing)CHF3.94M
Price to Earnings (P/E)498.6
Beta1.36
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding39,179,276
10 Day Avg. Volume110,510
30 Day Avg. Volume128,868
Financial Highlights & Ratios
PEG Ratio-3.21
Price to Book (P/B)15.78
Price to Sales (P/S)8.71
P/FCF Ratio-439.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF38.00Price Target Upside34.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.4
Revenue Forecast (FY)CHF227.92M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained multi-year revenue scaling indicates expanding clinical adoption and commercial traction for MagnetOs products. Growing top-line supports operating leverage, improves bargaining with distributors/hospitals, and creates a larger base to absorb costs and fund continued commercialization over the medium term.
High Gross MarginsVery high gross margins provide durable structural profitability potential and pricing flexibility for a specialized medical device. This margin profile supports reinvestment in sales and R&D while insulating operating results from some cost shocks, enhancing long-term business resilience as volume grows.
Conservative Balance SheetLow leverage and growing asset base give the company financial flexibility to fund expansion, absorb cash volatility, or pursue strategic investments without immediate refinancing pressure. This reduces solvency risk and supports execution of commercialization plans over the next several quarters.
Bears Say
Weak Cash GenerationNegative operating and free cash flow despite reported profits signals poor cash conversion. Persistent cash deficits can compel external financing or slower reinvestment, increasing dilution or interest burdens and constraining the company's ability to fund sales expansion and manufacturing scale sustainably.
Thin Profitability CushionProfitability has only just emerged and margins remain thin, leaving limited buffer against volume, pricing, or reimbursement setbacks. A small adverse change in procedure volumes or pricing could quickly eliminate net profits and hinder capacity to self-fund growth or cover unexpected costs.
Funding Sensitivity / Cash Conversion DragMismatch between accounting profitability and cash flow suggests working-capital pressure or investment spikes. If this persists, the company will remain sensitive to capital markets conditions and may face higher funding costs or dilution when raising cash, constraining strategic optionality in the medium term.
Kuros Biosciences News
KURN FAQ
What was Kuros Biosciences Ltd.’s price range in the past 12 months?
Kuros Biosciences Ltd. lowest stock price was CHF14.00 and its highest was CHF34.20 in the past 12 months.
What is Kuros Biosciences Ltd.’s market cap?
Kuros Biosciences Ltd.’s market cap is CHF910.53M.
When is Kuros Biosciences Ltd.’s upcoming earnings report date?
Kuros Biosciences Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 132 days.
How were Kuros Biosciences Ltd.’s earnings last quarter?
Kuros Biosciences Ltd. released its earnings results on Mar 10, 2026. The company reported CHF0.093 earnings per share for the quarter, beating the consensus estimate of CHF0 by CHF0.093.
Is Kuros Biosciences Ltd. overvalued?
According to Wall Street analysts Kuros Biosciences Ltd.’s price is currently Undervalued.
Does Kuros Biosciences Ltd. pay dividends?
Kuros Biosciences Ltd. does not currently pay dividends.
What is Kuros Biosciences Ltd.’s EPS estimate?
Kuros Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kuros Biosciences Ltd. have?
Kuros Biosciences Ltd. has 39,179,276 shares outstanding.
What happened to Kuros Biosciences Ltd.’s price movement after its last earnings report?
Kuros Biosciences Ltd. reported an EPS of CHF0.093 in its last earnings report, beating expectations of CHF0. Following the earnings report the stock price went up 10.609%.
Which hedge fund is a major shareholder of Kuros Biosciences Ltd.?
Currently, no hedge funds are holding shares in CH:KURN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kuros Biosciences Ltd.
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.
KURN Company Deck
KURN Earnings Call
Q4 2026
0:00 / 0:00
KURN Stock 12 Month Forecast
Average Price Target
CHF38.00
▲(34.94% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Options Prices
Currently, No data available
---